Robert M. Myers
Founder at Orbus Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ernest Mario | M | 85 |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | 18 years |
Jason D. Levin | M | - |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | - |
Patrick Enright | M | 62 |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | 9 years |
Kurt von Emster | M | 56 |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | 4 years |
Terry Gould | M | 67 |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | 9 years |
Alex Zisson | M | 54 |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Martin S. Gerstel | M | 83 | 25 years | |
Geoff Duyk | M | 64 | 7 years | |
Jane E. Shaw | M | 84 | 24 years | |
Deborah Burke | F | - | - | |
Peter Staple | M | 72 | 8 years | |
Bruce Cozadd | M | 60 | 11 years | |
Michael W. Ramsay | M | 67 | 2 years | |
Christopher Dammann | M | 54 | 1 years | |
Asha Ramdas | F | - | - | |
Carolyn Feamster | F | - | - | |
Padmanabh P. Bhatt | M | 66 | 5 years | |
Ronald P. Haak | M | - | 14 years | |
Joel A. Fernandes | M | 54 | 3 years | |
David Banks | M | - | 6 years | |
Yifan Zhai | M | 62 | 2 years | |
Erik D. Wiberg | M | - | 8 years | |
Casey C. Kopczynski | M | 62 | 6 years | |
Michael DesJardin | M | 66 | 9 years | |
Felissa H. Cagan | F | - | 3 years | |
Diane R. Guinta | M | - | 11 years | |
George Tyson | M | - | 9 years | |
Aron M. Knickerbocker | M | 54 | 1 years | |
Carole Roth | F | - | 7 years | |
Rekha Hemrajani | F | 54 | 8 years | |
Jeff Hargroves | M | 58 | 3 years | |
Suneel Gupta | M | 66 | 12 years | |
Wally Reiher | M | - | 12 years | |
An Cloet | F | 53 | 1 years | |
Valerie Pierce | F | 61 | 5 years | |
Ed F. Schnipper | M | 75 | 4 years | |
Jeffrey K. Tobias | M | 68 | 1 years | |
Susan P. Rinne | F | 72 | 11 years | |
Steven James | M | 66 | 1 years | |
Najafi Behrooz | M | - | 7 years | |
Michael Miller | M | 67 | 4 years | |
Detlef F. Albrecht | M | 63 | 10 years | |
Steven Ketchum | M | 59 | 8 years | |
Phyllis Gardner | M | 73 | 4 years | |
Howard Rosen | M | 66 | 10 years | |
Lupe M. Rivera | F | 57 | 9 years | |
Steve Cartt | M | 61 | 15 years | |
Kimberly Manhard | F | 64 | 1 years | |
Joan E. Colligan | F | - | 4 years | |
Barbara Finck | M | 77 | 2 years | |
Scott T. Shearer | M | 59 | 8 years | |
Samuel Saks | M | 69 | 2 years | |
James W. Young | M | 79 | 5 years | |
James Brown | M | 67 | 3 years | |
Felix Theeuwes | M | 86 | 29 years | |
Daniel Swisher | M | 61 | 9 years | |
Matthew Fust | M | 59 | 6 years | |
Carol A. Gamble | F | 71 | 12 years | |
Peter K. Working | M | 75 | 2 years | |
Krisztina Zsebo | M | 68 | - | |
Kevin Brodbeck | M | - | 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 61 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert M. Myers
- Personal Network